Advances in Therapy

, Volume 26, Issue 4, pp 369–382 | Cite as

Update on smoking cessation therapies

  • Deirdre A. Glynn
  • John F. Cryan
  • Pauline Kent
  • Robert A. Flynn
  • Marcus P. Kennedy


As a reflection of an exponential increase in smoking rates throughout the world during the last century, the economic and human burden of mortality and morbidity related to smoking is now clearly defined. Smoking cessation is associated with health benefits for people of all ages. In this paper we provide a comprehensive review of current licensed pharmacological smoking cessation agents including efficacy and safety profiles, with comparisons of individual therapies available. Furthermore, we offer a prospective on the need for further testing of other agents including novel avenues of therapy.


antidepressant bupropion chronic obstructive pulmonary disease ischemic heart disease lung cancer nicotine smoking tobacco vaccination varenicline 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mason RJ, Buist AS, Fisher EB, Merchant JA, Samet JM, Welsh CH. Cigarette smoking and health. Am Rev Respir Dis. 1985;132:1133–1136.PubMedGoogle Scholar
  2. 2.
    Centers for Disease Control and Prevention. Sample adult core component of the 1997-2006 National Health Interview Survey. Available at: Accessed March 4, 2009.
  3. 3.
    American Thoracic Society. Cigarette smoking and health. Am J Respir Crit Care Med. 1996;153:861–865.Google Scholar
  4. 4.
    Ezatti M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847–852.CrossRefGoogle Scholar
  5. 5.
    Centers for Disease Control and Prevention (CDC). Tobacco use — United States, 1900–1999. MMWR Morb Mortal Wkly Rep. 1999;48:986–993.Google Scholar
  6. 6.
    Centers for Disease Control and Prevention (CDC). Annual smoking attributable mortality, years of potential life lost, and economic costs - United States, 1995-1999. MMWR Morb Mortal Wkly Rep. 2002;51:300–303.Google Scholar
  7. 7.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation in mild to moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161:381–390.PubMedGoogle Scholar
  9. 9.
    Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General. Atlanta, GA: National Center of Chronic Disease Prevention and Health Promotion; 2004.Google Scholar
  10. 10.
    Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. Circulation. 2005;112:489–497.PubMedCrossRefGoogle Scholar
  11. 11.
    Godtfredsen NS, Holst C, Prescott E, et al. Smoking reduction, smoking cessation, and mortality: a 16 year follow up of 19,732 men and women from the Copenhagen centre for prospective population studies. Am J Epidemiol. 2002;156:994–1001.PubMedCrossRefGoogle Scholar
  12. 12.
    Samet JM. The health benefits of smoking cessation. Med Clin North Am. 1992;76:399–414.PubMedGoogle Scholar
  13. 13.
    Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of inhaled anticholinergic bronchodilators on the rate of decline of FEV1. JAMA. 1994;272:1497–1505.PubMedCrossRefGoogle Scholar
  14. 14.
    US Department of Health and Human Services. The health benefits of smoking cessation. A report of the Surgeon General, 1990. DHHS Publication No. (CDC) 90-8416. Rockville, MD: US Public Health Services, Office on Smoking and Health; 1990.Google Scholar
  15. 15.
    Taylor DH Jr, Hassalblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health. 2002;92:990–996.PubMedCrossRefGoogle Scholar
  16. 16.
    Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA. 2000;283:3244–3254.CrossRefGoogle Scholar
  17. 17.
    Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: an evidencebased clinical practice guideline for tobacco cessation. Chest. 2002;121:932–941.PubMedCrossRefGoogle Scholar
  18. 18.
    Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med. 2002;346:506–512.PubMedCrossRefGoogle Scholar
  19. 19.
    US Preventive Services Task Force. Counseling to prevent tobacco use and tobacco-caused disease: recommendation statement. Rockville, MD: Agency for Healthcare Research and Quality; 2003.Google Scholar
  20. 20.
    Office of the US Surgeon General. The health consequences of smoking: nicotine addiction: a report of the Surgeon General. DHHS Publication No. (CDC) 88-8406. Atlanta, GA: Centers for Health Promotion and Education, Office on Smoking and Health; 1988.Google Scholar
  21. 21.
    Henningfield JE, Stapelton JM, Benowitz NI, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33:23–29.PubMedCrossRefGoogle Scholar
  22. 22.
    Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res. 2000;2:19–37.PubMedCrossRefGoogle Scholar
  23. 23.
    Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007;9:315–327.PubMedCrossRefGoogle Scholar
  24. 24.
    Fiore MC, Jaen CR, Baker TB, et al. Clinical practice guideline: treating tobacco use and dependence 2008 update. Rockville, MD: Department of Health and Human Services; 2008.Google Scholar
  25. 25.
    Okuyeni KS, Ahluwalia JS, Harris KJ. Pharmacotherapy of smoking cessation. Arch Fam Med. 2000;9:270–281.CrossRefGoogle Scholar
  26. 26.
    Molyneux A. Nicotine replacement therapy. BMJ. 2004;328:454–456.PubMedCrossRefGoogle Scholar
  27. 27.
    Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146.Google Scholar
  28. 28.
    Lam W, Sze PC, Sacks HS, Chalmers TC. Metaanalysis of randomised controlled trials of nicotine chewing-gum. Lancet. 1987;2:27–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Schneider NG, Lunell E, Olmstead RE, Fagerström KO. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet. 1996;31:65–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994;271:1940–1947.PubMedCrossRefGoogle Scholar
  31. 31.
    Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction. 1995;90:1671–1682.PubMedCrossRefGoogle Scholar
  32. 32.
    Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008;(1):CD000146.Google Scholar
  33. 33.
    Hajek R, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med. 2000;159;2033–2038.CrossRefGoogle Scholar
  34. 34.
    Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo controlled trial. Arch Intern Med. 2000;160:3128–3134.PubMedCrossRefGoogle Scholar
  35. 35.
    Benowitz NL, Steven GG. Cardiovascular toxicity of nicotine: implication for nicotine replacement therapy. J Am Coll Cardiol. 1997;7:1422–1437.CrossRefGoogle Scholar
  36. 36.
    Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf. 2001;24:277–322.PubMedCrossRefGoogle Scholar
  37. 37.
    Coleman T, Britton J, Thornton J. Nicotine replacement therapy in pregnancy. BMJ. 2004;328;965–966.PubMedCrossRefGoogle Scholar
  38. 38.
    Rose JE. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl). 2006;184:274–285.CrossRefGoogle Scholar
  39. 39.
    Balfour DJ. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int J Clin Pract. 2001;55:53–57.PubMedGoogle Scholar
  40. 40.
    Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;(1):CD000031.Google Scholar
  41. 41.
    Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56:395–401.PubMedGoogle Scholar
  42. 42.
    Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA. Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther. 2001;298:651–657.PubMedGoogle Scholar
  43. 43.
    Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology. 2002;163:102–105.PubMedCrossRefGoogle Scholar
  44. 44.
    Semmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295:321–327.Google Scholar
  45. 45.
    Hurt RD, Sachs DPL, Glover ED, et al. A comparison of slow release buproprion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202.PubMedCrossRefGoogle Scholar
  46. 46.
    Swan GE, McAfee T, Curry SJ, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med. 2003;163:2337–2344.PubMedCrossRefGoogle Scholar
  47. 47.
    Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–691.PubMedCrossRefGoogle Scholar
  48. 48.
    Fiore MC, Bailey WC, Cohen SJ et al. Treating tobacco use and dependence. Rockville, MD: Department of Health and Human Services, Public Health Service; 2000.Google Scholar
  49. 49.
    Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Ostruct Pulmon Dis. 2008;3:45–53.Google Scholar
  50. 50.
    Slater YE, Houlihan LM, Maskell PD et al. Halogenated cytosine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology. 2003;44:503–515.PubMedCrossRefGoogle Scholar
  51. 51.
    Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474–3477.PubMedCrossRefGoogle Scholar
  52. 52.
    Aveyard P, West R. Managing smoking cessation. BMJ. 2007;335:37–41.PubMedCrossRefGoogle Scholar
  53. 53.
    Jorenby DE, Hays JT, Rigotti NA, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.PubMedCrossRefGoogle Scholar
  54. 54.
    Tonstad S, Tonnensen P, Hajek P, Williams KE, Billing CB, Reeves KR. Varenicline Phase 3 Study Group. Effects of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64–71.PubMedCrossRefGoogle Scholar
  55. 55.
    Gonzales D, Rennard SI, Nides M, et al. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist vs sustained release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55.PubMedCrossRefGoogle Scholar
  56. 56.
    Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179:135–144.PubMedGoogle Scholar
  57. 57.
    Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103:146–154.PubMedCrossRefGoogle Scholar
  58. 58.
    Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63:717–724.PubMedCrossRefGoogle Scholar
  59. 59.
    Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med. 2008;359:2018–2024.PubMedCrossRefGoogle Scholar
  60. 60.
    US Drug and Food Administration, Center for Drug Evaluation and Research. Varenicline [marketed as Chantix] information. Washington, DC: US Department of Health and Human Services; 2008.Google Scholar
  61. 61.
    Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34:121–130.PubMedCrossRefGoogle Scholar
  62. 62.
    Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med. 2006;166:1553–1559.PubMedCrossRefGoogle Scholar
  63. 63.
    Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000058.Google Scholar
  64. 64.
    Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165:1600–1605.PubMedCrossRefGoogle Scholar
  65. 65.
    George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O’Malley SS. A preliminary placebocontrolled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;53:136–143.PubMedCrossRefGoogle Scholar
  66. 66.
    Jarvik ME, Caskey NH, Wirshing WC, et al. Bromocriptine reduces cigarette smoking. Addiction. 2000;95:1173–1183.PubMedCrossRefGoogle Scholar
  67. 67.
    Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev. 2007;(4):CD005353.Google Scholar
  68. 68.
    Cryan JF, Gasparini F, van Heeke G, Markou A. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov Today. 2003;8:1025–1034.PubMedCrossRefGoogle Scholar
  69. 69.
    Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE. 2008;3:e2547.PubMedCrossRefGoogle Scholar
  70. 70.
    Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995;155:1933–1941.PubMedCrossRefGoogle Scholar
  71. 71.
    Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med. 2008;168:1950–1960.PubMedCrossRefGoogle Scholar
  72. 72.
    Stratelis G, Mölstad S, Jakobsson P, Zetterström O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care. 2006;24:133–139.PubMedCrossRefGoogle Scholar
  73. 73.
    Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years observation on male British doctors. BMJ. 2004;328:1519.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare Communications 2009

Authors and Affiliations

  • Deirdre A. Glynn
    • 1
  • John F. Cryan
    • 2
  • Pauline Kent
    • 1
  • Robert A. Flynn
    • 1
  • Marcus P. Kennedy
    • 1
  1. 1.Department of Medicine, Sligo General HospitalThe Mall, Co. SligoSligoRepublic of Ireland
  2. 2.Department of Pharmacology and Therapeutics, School of PharmacyUniversity College CorkCorkRepublic of Ireland

Personalised recommendations